Keravis, Thérèse <br/><br/>
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.  [electronic resource] 

 -  PloS one  2012 
 - e28899 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0028899  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Animals<br/>Cyclic AMP--metabolism<br/>Cyclic Nucleotide Phosphodiesterases, Type 4--chemistry<br/>Disease Progression<br/>Female<br/>Humans<br/>Isoenzymes<br/>Kidney--cytology<br/>Lipopolysaccharides--pharmacology<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Mice<br/>Mice, Inbred CBA<br/>Mice, Inbred MRL lpr<br/>Pentoxifylline--therapeutic use<br/>Phosphodiesterase 4 Inhibitors--therapeutic use<br/>Proteinuria--drug therapy<br/>Survival Rate<br/>Tumor Necrosis Factor-alpha--metabolism<br/>Xanthines--therapeutic use